

#### **Safe Harbor Statement**




Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.





### Biocon has consistently unlocked value over four decades

#### Biocon has benefited from transformational moves every decade



# **Biosimilar Value Chain**

# Mapping Biocon Biologics capabilities as a biosimilars company



#### **Emerging Markets**

**Developed Markets** 

PRODUCT DEVELOPMENT

CLINICAL TRIALS

REGULATORY

MANUFACTURING

SUPPLY CHAIN

COMMERCIALIZATION

























## Viatris' biosimilars business adds financial depth and commercial capabilities



1

**Financial** 

BBL to realize full revenue and profits from all its collaboration programs

Revenue EBITDA
\$1.1b | \$250m
Viatris Biosimilars
CY23 estimate<sup>1</sup>

2

**Operational** 

Commercialization, Supply Chain and Regulatory capabilities in Developed Markets









3

New Growth Drivers Launch of collaboration products in the US

Option for new in-licensed biosimilar asset

bBevacizumab bAspart bAdalimumab bAflibercept

Viatris to provide commercial and transition services for an expected two-year period, at cost plus \$44m p.a.

#### **Considerations to Viatris**



1

Cash Payment of \$2b at Closing

(\$50m payment from Viatris for capex funding)

\$1,950m

2

**Compulsorily Convertible Preference Shares** 

(represents an equity stake of at least 12.9%)

\$1,000m

Total considerations at

3

**Deferred consideration** 

(payment due in FY25)

\$160m

\$1b of CCPS

\$2.3b in cash and

4

**Option to acquire bAflibercept** 

(payment due in FY25)

\$175m

Viatris will have one nominee on the Board of Biocon Biologics

Strictly Confidential 6

### Financing the acquisition



\$1,950m **Payment at Closing Combination of equity and debt Equity commitment** \$800m received Well positioned to fund the acquisition **Debt commitment** \$1,800m received \$335m **Deferred Considerations** Primarily through cash generated from the business

7

# **Biosimilar Value Chain**

## Biocon Biologics to be a fully integrated global biosimilars company...





**Developed Markets** 

**Biocon Biologics POST ACQUISITION** 

**Global markets** 













PRODUCT DEVELOPMENT



**Emerging Markets** 















REGULATORY

CLINICAL TRIALS

MANUFACTURING





## ...with a comprehensive portfolio providing scale and future growth



2-4 years >4 years < 2 years Today - Pegfilgrastim - Bevacizumab (US) - Aflibercept - Pertuzumab - Trastuzumab - Aspart (US) Two undisclosed - Glargine 300 IU programs - Bevacizumab (EU) - Seven undisclosed - Adalimumab (US) programs - Glargine 100 IU - rH-Insulin (US) - Aspart (EU) - Vaccines (SILS - Adalimumab (EU) collaboration) - Etanercept (EU)

**7** Commercialized in Global Markets

20 Biosimilars in Portfolio

#### Building an organization for the next decade



#### Key investment highlights

- 1 Fully integrated global biosimilars company (lab to market)
  - 2 Strong commercial presence in global markets
    - 3 Comprehensive portfolio of biosimilars and vaccines
- **Biocon Biologics**
- 4 Global scale biologics manufacturing capacity
- 5 Experienced management team with strong execution capabilities
- 6 Strong business financials enabling long-term growth

Q&A

